The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Recombinant Vector Vaccines Market Research Report 2022

Global Recombinant Vector Vaccines Market Research Report 2022

Publishing Date : Jul, 2022

License Type :
 

Report Code : 1453059

No of Pages : 96

Synopsis
Recombinant vector vaccines are experimental vaccines similar to DNA vaccines, but they use an attenuated virus or bacterium to introduce microbial DNA to cells of the body. “Vector” refers to the virus or bacterium used as the carrier.
In nature, viruses latch on to cells and inject their genetic material into them. In the lab, scientists have taken advantage of this process. They have figured out how to take the roomy genomes of certain harmless or attenuated viruses and insert portions of the genetic material from other microbes into them. The carrier viruses then ferry that microbial DNA to cells. Recombinant vector vaccines closely mimic a natural infection and therefore do a good job of stimulating the immune system.
Attenuated bacteria also can be used as vectors. In this case, the inserted genetic material causes the bacteria to display the antigens of other microbes on its surface. In effect, the harmless bacterium mimics a harmful microbe, provoking an immune response.
Researchers are working on both bacteria-l and viral-based recombinant vector vaccines for HIV, rabies, and measles.
Due to the COVID-19 pandemic, the global Recombinant Vector Vaccines market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Recombinant Vector Vaccines market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Recombinant Vector Vaccines landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Varicella accounting for % of the Recombinant Vector Vaccines global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While For Adult segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Recombinant Vector Vaccines include SANOFI PASTEUR S.A., Novartis, GSK, CNBG, ChengDa Bio, Changsheng Life, Zhifei, SINOVAC BIOTECH and NuoCheng Bio, etc. In terms of revenue, the global 3 largest players have a % market share of Recombinant Vector Vaccines in 2021.
This report focuses on Recombinant Vector Vaccines volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Recombinant Vector Vaccines market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Recombinant Vector Vaccines Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type

  • Varicella
  • Influenza
  • Polio
  • Hepatitis A
  • Rabies
  • BCG
  • Hepatitis B
  • Pertussis, Diphtheria, tetanus
  • Pneumococcal
  • Others

Segment by Application

  • For Adult
  • For Child

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia) 
  • Asia-Pacific (China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia)
  • Latin America (Mexico, Brazil, Argentina, Colombia)

By Company

  • SANOFI PASTEUR S.A.
  • Novartis
  • GSK
  • CNBG
  • ChengDa Bio
  • Changsheng Life
  • Zhifei
  • SINOVAC BIOTECH
  • NuoCheng Bio
  • Hualan Bio
  • Kangtai
Index

1 Recombinant Vector Vaccines Market Overview
1.1 Product Overview and Scope of Recombinant Vector Vaccines
1.2 Recombinant Vector Vaccines Segment by Type
1.2.1 Global Recombinant Vector Vaccines Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Varicella
1.2.3 Influenza
1.2.4 Polio
1.2.5 Hepatitis A
1.2.6 Rabies
1.2.7 BCG
1.2.8 Hepatitis B
1.2.9 Pertussis, Diphtheria, tetanus
1.2.10 Pneumococcal
1.2.11 Others
1.3 Recombinant Vector Vaccines Segment by Application
1.3.1 Global Recombinant Vector Vaccines Sales Comparison by Application: (2022-2028)
1.3.2 For Adult
1.3.3 For Child
1.4 Global Recombinant Vector Vaccines Market Size Estimates and Forecasts
1.4.1 Global Recombinant Vector Vaccines Revenue 2017-2028
1.4.2 Global Recombinant Vector Vaccines Sales 2017-2028
1.4.3 Recombinant Vector Vaccines Market Size by Region: 2017 Versus 2021 Versus 2028
2 Recombinant Vector Vaccines Market Competition by Manufacturers
2.1 Global Recombinant Vector Vaccines Sales Market Share by Manufacturers (2017-2022)
2.2 Global Recombinant Vector Vaccines Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Recombinant Vector Vaccines Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Recombinant Vector Vaccines Manufacturing Sites, Area Served, Product Type
2.5 Recombinant Vector Vaccines Market Competitive Situation and Trends
2.5.1 Recombinant Vector Vaccines Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Recombinant Vector Vaccines Players Market Share by Revenue
2.5.3 Global Recombinant Vector Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Recombinant Vector Vaccines Retrospective Market Scenario by Region
3.1 Global Recombinant Vector Vaccines Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Recombinant Vector Vaccines Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Recombinant Vector Vaccines Market Facts & Figures by Country
3.3.1 North America Recombinant Vector Vaccines Sales by Country
3.3.2 North America Recombinant Vector Vaccines Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Recombinant Vector Vaccines Market Facts & Figures by Country
3.4.1 Europe Recombinant Vector Vaccines Sales by Country
3.4.2 Europe Recombinant Vector Vaccines Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Recombinant Vector Vaccines Market Facts & Figures by Region
3.5.1 Asia Pacific Recombinant Vector Vaccines Sales by Region
3.5.2 Asia Pacific Recombinant Vector Vaccines Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Recombinant Vector Vaccines Market Facts & Figures by Country
3.6.1 Latin America Recombinant Vector Vaccines Sales by Country
3.6.2 Latin America Recombinant Vector Vaccines Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Recombinant Vector Vaccines Market Facts & Figures by Country
3.7.1 Middle East and Africa Recombinant Vector Vaccines Sales by Country
3.7.2 Middle East and Africa Recombinant Vector Vaccines Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Recombinant Vector Vaccines Historic Market Analysis by Type
4.1 Global Recombinant Vector Vaccines Sales Market Share by Type (2017-2022)
4.2 Global Recombinant Vector Vaccines Revenue Market Share by Type (2017-2022)
4.3 Global Recombinant Vector Vaccines Price by Type (2017-2022)
5 Global Recombinant Vector Vaccines Historic Market Analysis by Application
5.1 Global Recombinant Vector Vaccines Sales Market Share by Application (2017-2022)
5.2 Global Recombinant Vector Vaccines Revenue Market Share by Application (2017-2022)
5.3 Global Recombinant Vector Vaccines Price by Application (2017-2022)
6 Key Companies Profiled
6.1 SANOFI PASTEUR S.A.
6.1.1 SANOFI PASTEUR S.A. Corporation Information
6.1.2 SANOFI PASTEUR S.A. Description and Business Overview
6.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.1.4 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Portfolio
6.1.5 SANOFI PASTEUR S.A. Recent Developments/Updates
6.2 Novartis
6.2.1 Novartis Corporation Information
6.2.2 Novartis Description and Business Overview
6.2.3 Novartis Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Novartis Recombinant Vector Vaccines Product Portfolio
6.2.5 Novartis Recent Developments/Updates
6.3 GSK
6.3.1 GSK Corporation Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.3.4 GSK Recombinant Vector Vaccines Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 CNBG
6.4.1 CNBG Corporation Information
6.4.2 CNBG Description and Business Overview
6.4.3 CNBG Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.4.4 CNBG Recombinant Vector Vaccines Product Portfolio
6.4.5 CNBG Recent Developments/Updates
6.5 ChengDa Bio
6.5.1 ChengDa Bio Corporation Information
6.5.2 ChengDa Bio Description and Business Overview
6.5.3 ChengDa Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.5.4 ChengDa Bio Recombinant Vector Vaccines Product Portfolio
6.5.5 ChengDa Bio Recent Developments/Updates
6.6 Changsheng Life
6.6.1 Changsheng Life Corporation Information
6.6.2 Changsheng Life Description and Business Overview
6.6.3 Changsheng Life Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Changsheng Life Recombinant Vector Vaccines Product Portfolio
6.6.5 Changsheng Life Recent Developments/Updates
6.7 Zhifei
6.6.1 Zhifei Corporation Information
6.6.2 Zhifei Description and Business Overview
6.6.3 Zhifei Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Zhifei Recombinant Vector Vaccines Product Portfolio
6.7.5 Zhifei Recent Developments/Updates
6.8 SINOVAC BIOTECH
6.8.1 SINOVAC BIOTECH Corporation Information
6.8.2 SINOVAC BIOTECH Description and Business Overview
6.8.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.8.4 SINOVAC BIOTECH Recombinant Vector Vaccines Product Portfolio
6.8.5 SINOVAC BIOTECH Recent Developments/Updates
6.9 NuoCheng Bio
6.9.1 NuoCheng Bio Corporation Information
6.9.2 NuoCheng Bio Description and Business Overview
6.9.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.9.4 NuoCheng Bio Recombinant Vector Vaccines Product Portfolio
6.9.5 NuoCheng Bio Recent Developments/Updates
6.10 Hualan Bio
6.10.1 Hualan Bio Corporation Information
6.10.2 Hualan Bio Description and Business Overview
6.10.3 Hualan Bio Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Hualan Bio Recombinant Vector Vaccines Product Portfolio
6.10.5 Hualan Bio Recent Developments/Updates
6.11 Kangtai
6.11.1 Kangtai Corporation Information
6.11.2 Kangtai Recombinant Vector Vaccines Description and Business Overview
6.11.3 Kangtai Recombinant Vector Vaccines Sales, Revenue and Gross Margin (2017-2022)
6.11.4 Kangtai Recombinant Vector Vaccines Product Portfolio
6.11.5 Kangtai Recent Developments/Updates
7 Recombinant Vector Vaccines Manufacturing Cost Analysis
7.1 Recombinant Vector Vaccines Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Recombinant Vector Vaccines
7.4 Recombinant Vector Vaccines Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Recombinant Vector Vaccines Distributors List
8.3 Recombinant Vector Vaccines Customers
9 Recombinant Vector Vaccines Market Dynamics
9.1 Recombinant Vector Vaccines Industry Trends
9.2 Recombinant Vector Vaccines Market Drivers
9.3 Recombinant Vector Vaccines Market Challenges
9.4 Recombinant Vector Vaccines Market Restraints
10 Global Market Forecast
10.1 Recombinant Vector Vaccines Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Recombinant Vector Vaccines by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Recombinant Vector Vaccines by Type (2023-2028)
10.2 Recombinant Vector Vaccines Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Recombinant Vector Vaccines by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Recombinant Vector Vaccines by Application (2023-2028)
10.3 Recombinant Vector Vaccines Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Recombinant Vector Vaccines by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Recombinant Vector Vaccines by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Tables

List of Tables
Table 1. Global Recombinant Vector Vaccines Sales Growth Rate Comparison by Type (2022-2028) & (K Doses) & (US$ Million)
Table 2. Global Recombinant Vector Vaccines Sales Growth Rate Comparison by Application (2022-2028) & (K Doses) & (US$ Million)
Table 3. Global Recombinant Vector Vaccines Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Recombinant Vector Vaccines Market Competitive Situation by Manufacturers in 2021
Table 5. Global Recombinant Vector Vaccines Sales (K Doses) of Key Manufacturers (2017-2022)
Table 6. Global Recombinant Vector Vaccines Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Recombinant Vector Vaccines Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Recombinant Vector Vaccines Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Recombinant Vector Vaccines Average Price (USD/Dose) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Recombinant Vector Vaccines Manufacturing Sites and Area Served
Table 11. Manufacturers Recombinant Vector Vaccines Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Recombinant Vector Vaccines by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Recombinant Vector Vaccines as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Recombinant Vector Vaccines Sales by Region (2017-2022) & (K Doses)
Table 16. Global Recombinant Vector Vaccines Sales Market Share by Region (2017-2022)
Table 17. Global Recombinant Vector Vaccines Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Recombinant Vector Vaccines Revenue Market Share by Region (2017-2022)
Table 19. North America Recombinant Vector Vaccines Sales by Country (2017-2022) & (K Doses)
Table 20. North America Recombinant Vector Vaccines Sales Market Share by Country (2017-2022)
Table 21. North America Recombinant Vector Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Recombinant Vector Vaccines Revenue Market Share by Country (2017-2022)
Table 23. Europe Recombinant Vector Vaccines Sales by Country (2017-2022) & (K Doses)
Table 24. Europe Recombinant Vector Vaccines Sales Market Share by Country (2017-2022)
Table 25. Europe Recombinant Vector Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Recombinant Vector Vaccines Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Recombinant Vector Vaccines Sales by Region (2017-2022) & (K Doses)
Table 28. Asia Pacific Recombinant Vector Vaccines Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Recombinant Vector Vaccines Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Recombinant Vector Vaccines Revenue Market Share by Region (2017-2022)
Table 31. Latin America Recombinant Vector Vaccines Sales by Country (2017-2022) & (K Doses)
Table 32. Latin America Recombinant Vector Vaccines Sales Market Share by Country (2017-2022)
Table 33. Latin America Recombinant Vector Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Recombinant Vector Vaccines Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Recombinant Vector Vaccines Sales by Country (2017-2022) & (K Doses)
Table 36. Middle East and Africa Recombinant Vector Vaccines Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Recombinant Vector Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Recombinant Vector Vaccines Revenue Market Share by Country (2017-2022)
Table 39. Global Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 40. Global Recombinant Vector Vaccines Sales Market Share by Type (2017-2022)
Table 41. Global Recombinant Vector Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Recombinant Vector Vaccines Revenue Share by Type (2017-2022)
Table 43. Global Recombinant Vector Vaccines Price by Type (2017-2022) & (USD/Dose)
Table 44. Global Recombinant Vector Vaccines Sales (K Doses) by Application (2017-2022)
Table 45. Global Recombinant Vector Vaccines Sales Market Share by Application (2017-2022)
Table 46. Global Recombinant Vector Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Recombinant Vector Vaccines Revenue Share by Application (2017-2022)
Table 48. Global Recombinant Vector Vaccines Price by Application (2017-2022) & (USD/Dose)
Table 49. SANOFI PASTEUR S.A. Corporation Information
Table 50. SANOFI PASTEUR S.A. Description and Business Overview
Table 51. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 52. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product
Table 53. SANOFI PASTEUR S.A. Recent Developments/Updates
Table 54. Novartis Corporation Information
Table 55. Novartis Description and Business Overview
Table 56. Novartis Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 57. Novartis Recombinant Vector Vaccines Product
Table 58. Novartis Recent Developments/Updates
Table 59. GSK Corporation Information
Table 60. GSK Description and Business Overview
Table 61. GSK Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 62. GSK Recombinant Vector Vaccines Product
Table 63. GSK Recent Developments/Updates
Table 64. CNBG Corporation Information
Table 65. CNBG Description and Business Overview
Table 66. CNBG Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 67. CNBG Recombinant Vector Vaccines Product
Table 68. CNBG Recent Developments/Updates
Table 69. ChengDa Bio Corporation Information
Table 70. ChengDa Bio Description and Business Overview
Table 71. ChengDa Bio Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 72. ChengDa Bio Recombinant Vector Vaccines Product
Table 73. ChengDa Bio Recent Developments/Updates
Table 74. Changsheng Life Corporation Information
Table 75. Changsheng Life Description and Business Overview
Table 76. Changsheng Life Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 77. Changsheng Life Recombinant Vector Vaccines Product
Table 78. Changsheng Life Recent Developments/Updates
Table 79. Zhifei Corporation Information
Table 80. Zhifei Description and Business Overview
Table 81. Zhifei Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 82. Zhifei Recombinant Vector Vaccines Product
Table 83. Zhifei Recent Developments/Updates
Table 84. SINOVAC BIOTECH Corporation Information
Table 85. SINOVAC BIOTECH Description and Business Overview
Table 86. SINOVAC BIOTECH Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 87. SINOVAC BIOTECH Recombinant Vector Vaccines Product
Table 88. SINOVAC BIOTECH Recent Developments/Updates
Table 89. NuoCheng Bio Corporation Information
Table 90. NuoCheng Bio Description and Business Overview
Table 91. NuoCheng Bio Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 92. NuoCheng Bio Recombinant Vector Vaccines Product
Table 93. NuoCheng Bio Recent Developments/Updates
Table 94. Hualan Bio Corporation Information
Table 95. Hualan Bio Description and Business Overview
Table 96. Hualan Bio Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 97. Hualan Bio Recombinant Vector Vaccines Product
Table 98. Hualan Bio Recent Developments/Updates
Table 99. Kangtai Corporation Information
Table 100. Kangtai Description and Business Overview
Table 101. Kangtai Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 102. Kangtai Recombinant Vector Vaccines Product
Table 103. Kangtai Recent Developments/Updates
Table 104. Production Base and Market Concentration Rate of Raw Material
Table 105. Key Suppliers of Raw Materials
Table 106. Recombinant Vector Vaccines Distributors List
Table 107. Recombinant Vector Vaccines Customers List
Table 108. Recombinant Vector Vaccines Market Trends
Table 109. Recombinant Vector Vaccines Market Drivers
Table 110. Recombinant Vector Vaccines Market Challenges
Table 111. Recombinant Vector Vaccines Market Restraints
Table 112. Global Recombinant Vector Vaccines Sales Forecast by Type (2023-2028) & (K Doses)
Table 113. Global Recombinant Vector Vaccines Sales Market Share Forecast by Type (2023-2028)
Table 114. Global Recombinant Vector Vaccines Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 115. Global Recombinant Vector Vaccines Revenue Market Share Forecast by Type (2023-2028)
Table 116. Global Recombinant Vector Vaccines Sales Forecast by Application (2023-2028) & (K Doses)
Table 117. Global Recombinant Vector Vaccines Sales Market Share Forecast by Application (2023-2028)
Table 118. Global Recombinant Vector Vaccines Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 119. Global Recombinant Vector Vaccines Revenue Market Share Forecast by Application (2023-2028)
Table 120. Global Recombinant Vector Vaccines Sales Forecast by Region (2023-2028) & (K Doses)
Table 121. Global Recombinant Vector Vaccines Sales Market Share Forecast by Region (2023-2028)
Table 122. Global Recombinant Vector Vaccines Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 123. Global Recombinant Vector Vaccines Revenue Market Share Forecast by Region (2023-2028)
Table 124. Research Programs/Design for This Report
Table 125. Key Data Information from Secondary Sources
Table 126. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Recombinant Vector Vaccines
Figure 2. Global Recombinant Vector Vaccines Market Share by Type in 2021 & 2028
Figure 3. Varicella Product Picture
Figure 4. Influenza Product Picture
Figure 5. Polio Product Picture
Figure 6. Hepatitis A Product Picture
Figure 7. Rabies Product Picture
Figure 8. BCG Product Picture
Figure 9. Hepatitis B Product Picture
Figure 10. Pertussis, Diphtheria, tetanus Product Picture
Figure 11. Pneumococcal Product Picture
Figure 12. Others Product Picture
Figure 13. Global Recombinant Vector Vaccines Market Share by Application in 2021 & 2028
Figure 14. For Adult
Figure 15. For Child
Figure 16. Global Recombinant Vector Vaccines Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 17. Global Recombinant Vector Vaccines Market Size (2017-2028) & (US$ Million)
Figure 18. Global Recombinant Vector Vaccines Sales (2017-2028) & (K Doses)
Figure 19. Recombinant Vector Vaccines Sales Share by Manufacturers in 2021
Figure 20. Global Recombinant Vector Vaccines Revenue Share by Manufacturers in 2021
Figure 21. The Global 5 and 10 Largest Recombinant Vector Vaccines Players: Market Share by Revenue in 2021
Figure 22. Recombinant Vector Vaccines Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 23. Global Recombinant Vector Vaccines Sales Market Share by Region (2017-2022)
Figure 24. Global Recombinant Vector Vaccines Sales Market Share by Region in 2021
Figure 25. Global Recombinant Vector Vaccines Revenue Market Share by Region (2017-2022)
Figure 26. Global Recombinant Vector Vaccines Revenue Market Share by Region in 2021
Figure 27. U.S. Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. Canada Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Germany Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. France Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. U.K. Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Italy Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. Russia Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. China Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Japan Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. South Korea Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. India Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Australia Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Taiwan Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Indonesia Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Thailand Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Malaysia Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Philippines Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Vietnam Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Mexico Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. Brazil Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 47. Argentina Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 48. Turkey Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 49. Saudi Arabia Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 50. U.A.E Recombinant Vector Vaccines Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 51. Sales Market Share of Recombinant Vector Vaccines by Type (2017-2022)
Figure 52. Manufacturing Cost Structure of Recombinant Vector Vaccines
Figure 53. Manufacturing Process Analysis of Recombinant Vector Vaccines
Figure 54. Recombinant Vector Vaccines Industrial Chain Analysis
Figure 55. Channels of Distribution
Figure 56. Distributors Profiles
Figure 57. Bottom-up and Top-down Approaches for This Report
Figure 58. Data Triangulation
Figure 59. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’